Passage Bio Inc (PASG) Stock AnalysisPASGStock AnalysisPassage Bio Inc

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Passage Bio is not a good buy right now due to its significant financial losses and uncertain future. The current price is $4.52, with a year-to-date decline of 61.33% and a forward P/E ratio of 0, indicating no earnings expected in the near future. The main risk is the company's ongoing negative net income, which reached -$19.34 million in Q3 2024 and has continued to decline, leading to a current ratio of 1.22, suggesting potential liquidity issues.